Integra LifeSciences Holdings CorporationIART
Key ratios
Operating cash flow growth
20.4%TTM
2025
-61.1%2024
-7.6%2023
-47.1%
EPS growth
-61.1%2023
FCF / Sales
1.6%TTM
2025
-1.9%2024
1.6%2023
4.7%
Net margin
-0.4%TTM
2025
-31.6%2024
-0.4%2023
4.4%
ROA
2.8%TTM
2025
2.4%2024
2.9%2023
1.8%
ROE
-0.7%TTM
2025
-39.9%2024
-0.4%2023
4.0%
Revenue growth
1.6%TTM
2025
1.5%2024
4.5%2023
-1.0%
Recent news
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
Integra LifeSciences Reports Third Quarter 2026 Financial Results
Integra Announces Completion of Refinancing Transactions
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
Integra Announces Pricing of Senior Secured Notes
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
Integra LifeSciences Announces 100th Patient Enrolled in AERA Pediatric Registry
Track IART in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer